# 99mTc-MIRC208 SPECT/CT Imaging for HER2-Positive Cancer Patients

> **NCT04591652** · NA · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 200 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** 99mTc-MIRC208

## Key facts

- **NCT ID:** NCT04591652
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2024-08-30
- **Final completion:** 2024-08-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04591652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04591652, "99mTc-MIRC208 SPECT/CT Imaging for HER2-Positive Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04591652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*